NASDAQ:CMMB Chemomab Therapeutics (CMMB) Stock Price, News & Analysis → Alert: Your Bank is Dying – Act Now or Lose Everything! (From Priority Gold) (Ad) Free CMMB Stock Alerts $1.38 +0.09 (+6.96%) (As of 08:53 AM ET) Add Compare Share Share Today's Range$1.38▼$1.3850-Day Range$0.59▼$1.2952-Week Range$0.42▼$1.77Volume1,253 shsAverage Volume179,044 shsMarket Capitalization$15.25 millionP/E RatioN/ADividend YieldN/APrice Target$5.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Chemomab Therapeutics alerts: Email Address Chemomab Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.25 Rating ScoreUpside/Downside310.7% Upside$5.67 Price TargetShort InterestHealthy0.88% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.51 out of 5 starsMedical Sector308th out of 904 stocksPharmaceutical Preparations Industry139th out of 428 stocks 3.6 Analyst's Opinion Consensus RatingChemomab Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageChemomab Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Chemomab Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.88% of the float of Chemomab Therapeutics has been sold short.Short Interest Ratio / Days to CoverChemomab Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chemomab Therapeutics has recently decreased by 10.71%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldChemomab Therapeutics does not currently pay a dividend.Dividend GrowthChemomab Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CMMB. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Chemomab Therapeutics this week, compared to 1 article on an average week.Search Interest4 people have searched for CMMB on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows4 people have added Chemomab Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Chemomab Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.91% of the stock of Chemomab Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions46.05% of the stock of Chemomab Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Chemomab Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Chemomab Therapeutics are expected to remain at ($0.90) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chemomab Therapeutics is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Chemomab Therapeutics is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChemomab Therapeutics has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Chemomab Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTICheck out WFC chartI’m about to go head-to-head with Wall Street… Exposing one of their BEST kept secrets… A secret that they’ve kept hidden in the dark for YEARS… And according to the backtest, it’s already shown the power to pay out… 28%... 41%... Even 83%... Not in a year… Not in a month… But in just 24 hours…You gotta click here because I’m about to show how to spot what could be the next one. About Chemomab Therapeutics Stock (NASDAQ:CMMB)Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Read More CMMB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMMB Stock News HeadlinesJune 6 at 7:00 AM | globenewswire.comChemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research ConferenceMay 17, 2024 | globenewswire.comChemomab Therapeutics to Participate in Upcoming Scientific ConferencesMay 14, 2024 | msn.comMaxim Group Initiates Coverage of Chemomab Therapeutics - Depositary Receipt () (CMMB) with Buy RecommendationMay 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Chemomab Therapeutics (CMMB), Fate Therapeutics (FATE) and Disc Medicine (IRON)May 9, 2024 | investorplace.comCMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q1 2024May 9, 2024 | globenewswire.comChemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 8, 2024 | globenewswire.comChemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RuleMay 2, 2024 | globenewswire.comChemomab Therapeutics to Present at 2024 Aegis Virtual ConferenceApril 24, 2024 | globenewswire.comChemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business UpdateApril 18, 2024 | globenewswire.comChemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic SclerosisApril 8, 2024 | finance.yahoo.comChemomab Therapeutics Ltd. (CMMB)April 2, 2024 | globenewswire.comChemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024March 25, 2024 | globenewswire.comChemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing CholangitisMarch 7, 2024 | investorplace.comCMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q4 2023March 7, 2024 | finanznachrichten.deChemomab Therapeutics Ltd: Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate UpdateMarch 7, 2024 | finance.yahoo.comChemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate UpdateMarch 5, 2024 | prnewswire.comChemomab Therapeutics to Participate in Leerink Global BioPharma ConferenceFebruary 20, 2024 | msn.comBiotech Shares Massively Bid Up Before Opening BellFebruary 20, 2024 | finance.yahoo.comChemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory DiseasesFebruary 20, 2024 | prnewswire.comChemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory DiseasesFebruary 14, 2024 | finance.yahoo.comChemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business UpdateFebruary 14, 2024 | prnewswire.comChemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business UpdateFebruary 5, 2024 | finance.yahoo.comChemomab Therapeutics to Participate in Upcoming Investor ConferencesJanuary 30, 2024 | finance.yahoo.comChemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing CholangitisJanuary 6, 2024 | benzinga.comChemomab Therapeutics Stock (NASDAQ:CMMB) Dividends: History, Yield and DatesSee More Headlines Receive CMMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/05/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CMMB CUSIPN/A CIK1534248 Webwww.chemomab.com Phone972-77-331-0156FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$5.67 High Stock Price Target$7.00 Low Stock Price Target$4.00 Potential Upside/Downside+339.3%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,220,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-109.92% Return on Assets-83.68% Debt Debt-to-Equity RatioN/A Current Ratio3.83 Quick Ratio3.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / Book0.84Miscellaneous Outstanding Shares11,050,000Free Float9,734,000Market Cap$14.25 million OptionableNot Optionable Beta0.48 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Adi Mor George Ph.D. (Age 42)Co-Founder, Chief Scientific Officer, CEO & Executive Director Comp: $330kMs. Sigal Fattal CPA (Age 53)M.B.A., Chief Financial Officer Comp: $322kDr. Matthew B. Frankel M.B.A. (Age 55)M.D., Chief Medical Officer & VP of Drug Development Comp: $850kBarbara LindheimConsulting Vice President of Investor & Public Relations, Strategic CommunicationsKey CompetitorsMural OncologyNASDAQ:MURACarisma TherapeuticsNASDAQ:CARMRockwell MedicalNASDAQ:RMTIKezar Life SciencesNASDAQ:KZRLexaria BioscienceNASDAQ:LEXXView All Competitors CMMB Stock Analysis - Frequently Asked Questions Should I buy or sell Chemomab Therapeutics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemomab Therapeutics in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CMMB shares. View CMMB analyst ratings or view top-rated stocks. What is Chemomab Therapeutics' stock price target for 2024? 4 brokerages have issued 1 year price targets for Chemomab Therapeutics' shares. Their CMMB share price targets range from $4.00 to $7.00. On average, they anticipate the company's share price to reach $5.67 in the next twelve months. This suggests a possible upside of 310.7% from the stock's current price. View analysts price targets for CMMB or view top-rated stocks among Wall Street analysts. How have CMMB shares performed in 2024? Chemomab Therapeutics' stock was trading at $0.51 at the start of the year. Since then, CMMB shares have increased by 170.5% and is now trading at $1.3798. View the best growth stocks for 2024 here. Are investors shorting Chemomab Therapeutics? Chemomab Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 104,200 shares, a decline of 10.7% from the April 30th total of 116,700 shares. Based on an average daily volume of 93,400 shares, the short-interest ratio is presently 1.1 days. Currently, 0.9% of the shares of the company are short sold. View Chemomab Therapeutics' Short Interest. When is Chemomab Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our CMMB earnings forecast. How were Chemomab Therapeutics' earnings last quarter? Chemomab Therapeutics Ltd. (NASDAQ:CMMB) announced its quarterly earnings results on Thursday, May, 9th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.08. How do I buy shares of Chemomab Therapeutics? Shares of CMMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CMMB) was last updated on 6/6/2024 by MarketBeat.com Staff From Our Partners"The Biggest Drug Ever" Is ComingUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Phar...Behind the Markets | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredEverything from semiconductors to space shuttles depend on this overlooked mineralBoron is also at the heart of a breakthrough that could fuel one of mankind's most sensational advances in sem...Capital Trends | Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC | SponsoredBitcoin’s Biggest Year Yet2024 is set to be a historic year for Bitcoin. It’s all thanks to three major catalysts that I reveal in my...Paradigm Press | SponsoredClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an eff...Crypto Swap Profits | SponsoredAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the big...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
